(NASDAQ: INMB) Inmune Bio's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 14.36%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 33.69%.
Inmune Bio's earnings in 2026 is -$45,933,000.On average, 6 Wall Street analysts forecast INMB's earnings for 2026 to be -$20,970,452, with the lowest INMB earnings forecast at -$27,356,230, and the highest INMB earnings forecast at -$15,352,986. On average, 5 Wall Street analysts forecast INMB's earnings for 2027 to be -$23,953,317, with the lowest INMB earnings forecast at -$28,398,373, and the highest INMB earnings forecast at -$14,236,406.
In 2028, INMB is forecast to generate -$12,338,218 in earnings, with the lowest earnings forecast at -$15,632,132 and the highest earnings forecast at -$8,653,501.